Cefmatilen (INN, codenamed S-1090) is an orally-active cephalosporin antibiotic. It was developed in Japan and first described in 1992.[1]
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C15H14N8O5S4 |
| Molar mass | 514.57 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
In vitro, cefmatilen is highly active against a variety of Gram-positive and Gram-negative bacteria, including Streptococcus pyogenes and Neisseria gonorrhoeae.[1]
References
edit- 1 2 Tsuji M, Ishii Y, Ohno A, Miyazaki S, Yamaguchi K (November 1995). "In vitro and in vivo antibacterial activities of S-1090, a new oral cephalosporin". Antimicrob Agents Chemother. 39 (11): 2544–51. doi:10.1128/aac.39.11.2544. PMC 162981. PMID 8585742.